Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Jan;11(1):1-5.
doi: 10.21037/jtd.2018.12.70.

From "high" ZEB1 to "low" B-cell lymphoma 2-interacting mediator of cell death (BIM)-an epithelial-mesenchymal transition (EMT)-associated drug resistance pathway elucidated

Fabrizio Marcucci  1 , Cristiano Rumio  1
Affiliations
Editorial

From "high" ZEB1 to "low" B-cell lymphoma 2-interacting mediator of cell death (BIM)-an epithelial-mesenchymal transition (EMT)-associated drug resistance pathway elucidated

Fabrizio Marcucci et al. J Thorac Dis. 2019 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Mechanism of Resistance towards EGFRi in Mesenchymal EGFR-Mutant Lung Cancer Cells towards EGFRi. EGFR-mutant lung cancers are constituted, to varying degrees, by tumor cells of predominantly epithelial phenotype, and lung cancer cells of predominantly mesenchymal phenotype. Cells with predominantly mesenchymal phenotype express high levels of the EMT transcriptional regulator ZEB1. ZEB1 binds directly to the promoter of the gene encoding the antiapoptotic protein B and represses its transcription. Low levels of BIM promote resistance to EGFRi and, possibly also to other antitumor drugs. Lung cancer cells with a predominantly epithelial phenotype express unrepressed levels of BIM and promote apoptosis towards EGFRi. BIM, BCL-2-interacting mediator of cell death; EGFR, epidermal growth factor receptor; EGFRi, EGFR inhibitor(s); EMT, epithelial-mesenchymal transcription.
See this image and copyright information in PMC

Comment in

Comment on

  • Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.
    Song KA, Niederst MJ, Lochmann TL, Hata AN, Kitai H, Ham J, Floros KV, Hicks MA, Hu H, Mulvey HE, Drier Y, Heisey DAR, Hughes MT, Patel NU, Lockerman EL, Garcia A, Gillepsie S, Archibald HL, Gomez-Caraballo M, Nulton TJ, Windle BE, Piotrowska Z, Sahingur SE, Taylor SM, Dozmorov M, Sequist LV, Bernstein B, Ebi H, Engelman JA, Faber AC. Song KA, et al. Clin Cancer Res. 2018 Jan 1;24(1):197-208. doi: 10.1158/1078-0432.CCR-17-1577. Epub 2017 Oct 19. Clin Cancer Res. 2018. PMID: 29051323 Free PMC article.

References

    1. Song KA, Niederst MJ, Lochmann TL, et al. Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM. Clin Cancer Res 2018;24:197-208. 10.1158/1078-0432.CCR-17-1577 - DOI - PMC - PubMed
    1. Marcucci F, Stassi G, De Maria R. Epithelial–mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov 2016;15:311-25. 10.1038/nrd.2015.13 - DOI - PubMed
    1. Marcucci F, Bellone M, Caserta CA, et al. Pushing tumor cells towards a malignant phenotype. Stimuli from the microenvironment, intercellular communications and alternative roads. Int J Cancer 2014;135:1265-76. 10.1002/ijc.28572 - DOI - PubMed
    1. Dumont N, Wilson MB, Crawford YG, et al. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U S A 2008;105:14867-72. 10.1073/pnas.0807146105 - DOI - PMC - PubMed
    1. Chung SS, Giehl N, Wu Y, et al. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol 2014;44:403-11. 10.3892/ijo.2013.2195 - DOI - PMC - PubMed